Clearside Biomedical Inc
NASDAQ:CLSD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Clearside Biomedical Inc
NASDAQ:CLSD
|
US |
|
I
|
ID Holdings Corp
TSE:4709
|
JP |
|
Carmax Inc
NYSE:KMX
|
US |
|
Delta Oil & Gas Inc
OTC:DLTA
|
CA |
|
S
|
Studentbostader I Norden AB (publ)
STO:STUDBO
|
SE |
|
P
|
Pacira Biosciences Inc
F:82P
|
US |
|
Gecina SA
PAR:GFC
|
FR |
|
ACQ Bure AB
F:0FE
|
SE |
|
Kaile Science and Technology Co Ltd Hubei
SSE:600260
|
CN |
|
Altus Power Inc
NYSE:AMPS
|
US |
|
A
|
Accelleron Industries AG
SIX:ACLN
|
CH |
|
D
|
Dongwha Enterprise Co Ltd
KOSDAQ:025900
|
KR |
|
Bjorn Borg AB
STO:BORG
|
SE |
|
P
|
Petroleum General Distribution Services JSC
VN:PSD
|
VN |
|
B
|
Beijing Andawell Science & Technology Co Ltd
SZSE:300719
|
CN |
|
Manulife Financial Corp
TSX:MFC
|
CA |
|
Q
|
Quest Holdings SA
ATHEX:QUEST
|
GR |
Clearside Biomedical Inc
Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company is headquartered in Alpharetta, Georgia and currently employs 34 full-time employees. The company went IPO on 2016-06-02. The firm is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. The company is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.
Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company is headquartered in Alpharetta, Georgia and currently employs 34 full-time employees. The company went IPO on 2016-06-02. The firm is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. The company is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
